ArticleTheranostics2022
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 4 pooled it
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Knowledge graph and frontier trends in melanoma-associated ncRNAs: a bibliometric analysis from 2006 to 2023.Frontiers in oncology · 2024Pooled it
- Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.Frontiers in oncology · 2024Pooled it
- Unlocking the potential of microRNA as predictive biomarkers for efficacy and adverse events in immune checkpoint inhibitor therapy (Review).Molecular medicine reports · 2026Review
- Microneedle-based theranostics for melanoma: Advances and outlook.Materials today. Bio · 2026Review
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.The journal of liquid biopsy · 2025Review
- Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanoma.Journal of translational medicine · 2025Article
- Cell-free and extracellular vesicle microRNAs with clinical utility for solid tumors.Molecular oncology · 2025Review
- The Role of Non-coding RNAs in Tumorigenesis, Diagnosis/Prognosis, and Therapeutic Strategies for Cutaneous Melanoma.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Decoding STAT3: a new frontier in understanding and treating hyperoxic lung injury.Frontiers in immunology · 2025Review
- Machine learning for catalysing the integration of noncoding RNA in research and clinical practice.EBioMedicine · 2024Review
- The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.Cell death & disease · 2024Article
- Article
- Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin.Journal of experimental & clinical cancer research : CR · 2023Article
- BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.Cancers · 2023Review
- The new world of RNA diagnostics and therapeutics.Journal of experimental & clinical cancer research : CR · 2023Article
- Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach.International journal of molecular sciences · 2023Review
- Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia.Theranostics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Ciro Francesco RuggieroDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Luigi FattoreSAFU Laboratory, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Irene TerrenatoUOSD Clinical Trial Center e Biostatistica e Bioinformatica, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Francesca SperatiUOSD Clinical Trial Center e Biostatistica e Bioinformatica, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Valentina SalvatiDepartment. Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Gabriele MadonnaDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Mariaelena CaponeDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Fabio ValentiOncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Simona Di MartinoBiological Tissue and Liquid Bank, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Chiara MandojClinical Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Domenico LiguoroDepartment of Molecular and Clinical Medicine, University of Rome "Sapienza", 00161 Rome, Italy.
Vittorio CastaldoDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Giordana CafaroDepartment. Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Ester SimeoneDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Vito VanellaDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Michelangelo RussilloDivision of Medical Oncology1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Laura ContiClinical Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giovanni CudaDepartment of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Diana GiannarelliUOSD Clinical Trial Center e Biostatistica e Bioinformatica, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Paolo Antonio AsciertoDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy.
Rita ManciniDepartment of Molecular and Clinical Medicine, University of Rome "Sapienza", 00161 Rome, Italy.
Gennaro CilibertoScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITMagna Graecia University · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Circulating MicroRNAMelanomaMicroRNAsSkin NeoplasmsBiomarkers, TumorHumansProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, humanCirculating MicroRNAMicroRNAsMIRN4488 microRNA, humanMIRN579 microRNA, humanProto-Oncogene Proteins B-rafbiomarkersliquid biopsymetastatic melanomamicroRNAtarget therapy.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.